November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
July 24, 2023
Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders
Gadiyar, V., Patel, G., Chen, J., Vigil, D., Ji, N., Campbell, V., Sharma, K., Shi, Y., Weiss, M., Birge, R., & Davra, V.
Read More
December 7, 2022
Proteomics enabling TPD Drug Discovery
TPD Assay Development and Screening Summit
Read More
October 25, 2022
Expression & Characterization of Novel Tissue Selective E3 Ligases
5th Annual Targeted Protein Degradation (TPD) Summit
Read More
August 15, 2022
MQAtlas Creates a Deep, Accurate and Global E3 Expression Atlas Enabling Targeted Protein Degradation Based Precision Medicine
The 14th International Symposium on Mass Spectrometry in the Health and Life Sciences
Read More
June 7, 2022
Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications
Targeting protein degradation 3 – from discovery to the clinic (TPD3)
MYD88 Tumors
Read More
June 6, 2022
Discovery and targeted mass spectrometry-based proteomics: Enabling technologies advancing IRAK4 protein degrader along the drug discovery pipeline into the clinic
The American Society for Mass Spectrometry (ASMS) Annual Conference
Read More
May 31, 2022
STAT3 degraders inhibit Th17 development and cytokine production resulting in profound inhibition of collagen-induced autoimmune murine arthritis
European Alliance of Associations for Rheumatology (EULAR) 2022 Annual Congress
Read More
May 17, 2022
Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets
Society for Investigative Dermatology (SID) 2022 Annual Meeting
Read More
May 10, 2022
Non-Clinical Safety Considerations when Developing Targeted Protein Degraders
Applied Pharmaceutical Toxicology (APT) 2022
Read More